This is the authors' abstract. We don't add key points for this paper.
To explore the efficacy and safety of ibrutinib for the treatment of newly treated and relapsed refractory (R/R) lymphoplasmacytic lymphoma (LPL) /Waldenström macroglobulinemia (WM) .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: